Duopharma Biotech Berhad, (7148) Fair Value & Analysis
Healthcare · MY · Market cap 1.2B MYR
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Share price −0.8% over the past month.
A solid business, screening 63% undervalued on our models.
What matters now
- Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (1.16 MYR to 2.50 MYR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 0.9753 MYR – 2.23 MYR · fair‑value band 1.16 MYR – 2.50 MYR · the 1.23 MYR price screens below the 2.00 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Duopharma Biotech Berhad, (7148) currently trades at 1.23 MYR, while our model-based Fair Value estimate is 2.00 MYR, implying the stock looks roughly 62.6% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Duopharma Biotech Berhad, generated revenue of 917M MYR at a net margin of 10.1%. Revenue declined 5.7% year over year. It earns a return on equity of 12.6%. Net debt stands at 202M MYR. Fundamentals as of Jul 12, 2026
Our scenario range runs from 1.16 MYR (bear case) to 2.50 MYR (bull case); at 1.23 MYR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 63%, 7148 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (1.91 MYR) versus Dividend Discount (0.4500 MYR). Highest evidence: Growth DCF (80).
Notify me when 7148 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally.
Full company description
Duopharma Biotech Berhad, together with its subsidiaries, researches, develops, manufactures, markets, sells, imports, and distributes pharmaceutical products and medicines in Malaysia and internationally. It offers consumer healthcare products, including vitamins, minerals, and supplements under the Flavettes, PROVITON, PROVITON STR, CHAMPS, and Naturalle brand names; analgesics and antitussives under the Uphamol, Uphacol, and Uphaplast brand names; eyecare products under the Eye Glo brand name; antacids under the Alucid brand name; joint pain products under the Donna brand name; skincare products under Dermoplex brand name; cosmeceuticals under the IRORO Nutreatment brand name; and functional food under the CHAMPS Nutribar and PROVITON STR Powerz brand names. The company also provides generic drugs for various therapeutic areas, such as cardiovascular, dermatology, hormonal, respiratory, sensory and nervous system, musculoskeletal, anti-infectives, and others; and specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables for the treatment of diabetes, cancer, cardiovascular, renal, and other diseases. In addition, it engages in the development of small molecules and biologic therapies for the treatment of Alzheimer's disease; digital therapeutics; and stem cell therapies. Further, the company is involved in property management and services; and distribution of chemical products. It exports its products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. Duopharma Biotech Berhad was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Duopharma Biotech Berhad, reported revenue of 932M MYR in FY2025 versus 639M MYR in FY2021, a compound +9.9%/yr. Reported net income was 87.5M MYR in FY2025, compounding +7.4%/yr from FY2021.
of which total revenue +13.9 pp · buybacks/dilution −2.7 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 7148: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Duopharma Biotech Berhad, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Duopharma Biotech Berhad, (7148) overvalued or undervalued?
What is the fair value of 7148?
What is the quality score of 7148?
What is the revenue of Duopharma Biotech Berhad, (7148)?
What is the net profit margin of 7148?
Does Duopharma Biotech Berhad, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Duopharma Biotech Berhad, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.